Heberprot-P vs. U.S. Wound Care: A Comparison for American Diabetics

Understanding the Difference

American diabetic patients with non-healing foot ulcers have access to advanced wound care technologies — but some wounds still fail to heal. Understanding how Cuba's Heberprot-P differs from U.S. standard wound care helps patients make informed decisions about when to consider traveling to Cuba.

The key difference: Heberprot-P delivers recombinant human Epidermal Growth Factor (hEGF) directly into the wound via intralesional injection — a mechanism not available through any FDA-approved product in the United States. While U.S. wound care offers advanced dressings, negative pressure therapy, hyperbaric oxygen, and skin substitutes, none of these deliver growth factor directly to the wound cells in the way Heberprot-P does.

U.S. Standard Wound Care Options

Current U.S. treatments for diabetic foot ulcers include:

• Standard wound care — Debridement, moist wound dressings, offloading (total contact cast), infection management, glycemic control. The foundation of all diabetic foot ulcer treatment, available in Cuba too. • Negative pressure wound therapy (NPWT / wound VAC) — Applies continuous or intermittent negative pressure to the wound to promote granulation and fluid removal. Costs $150-$200/day. • Hyperbaric oxygen therapy (HBOT) — Patient breathes 100% oxygen in a pressurized chamber to increase oxygen delivery to the wound. Requires 20-40 sessions at $200-$500 each. • Skin substitutes / cellular tissue products — Bioengineered skin products (Dermagraft, Apligraf, Grafix, etc.) applied to the wound to provide a scaffold for healing. $1,000-$3,000 per application. • Becaplermin (Regranex) — A topical gel containing recombinant human Platelet-Derived Growth Factor (PDGF). This is the closest U.S. equivalent to Heberprot-P, but it's a different growth factor (PDGF vs. EGF), applied topically rather than injected, and has a black-box warning for cancer risk. • Surgical revascularization — For ulcers with poor blood flow due to peripheral arterial disease, vascular surgery (bypass or angioplasty) may be needed to restore blood supply. • Amputation — When all other treatments fail, amputation becomes the last resort.

Despite these options, many diabetic foot ulcers in the U.S. remain non-healing, leading to approximately 130,000 amputations annually.

How Heberprot-P Is Different

Heberprot-P offers a unique mechanism not available in U.S. wound care:

• Growth factor: EGF (Epidermal Growth Factor) — Heberprot-P delivers hEGF, which specifically stimulates the proliferation and migration of keratinocytes, fibroblasts, and endothelial cells — the cells needed for wound closure. • Delivery: Intralesional injection — Unlike topical applications (Regranex gel, dressings), Heberprot-P is injected directly into the wound edges, delivering concentrated growth factor precisely where cellular activity needs to be stimulated. This bypasses the barrier of the wound surface and delivers the active agent deep into the wound tissue. • Concentration: Therapeutic dose — The injected dose provides a much higher local concentration of growth factor than topical applications can achieve. • Frequency: 3 times per week — Regular, repeated stimulation of the wound healing process over up to 8 weeks. • Combination: With standard wound care — Heberprot-P is not a replacement for debridement, offloading, infection management, and glycemic control. It is used in combination with these standard measures.

The closest U.S. product, Regranex (becaplermin), delivers a different growth factor (PDGF, not EGF) topically rather than by injection. Regranex also carries a black-box warning for increased cancer mortality risk, which has limited its use. Heberprot-P's intralesional EGF delivery represents a different therapeutic approach.

When to Consider Traveling to Cuba for Heberprot-P

American patients should consider Heberprot-P treatment in Cuba when:

• The ulcer has failed standard U.S. wound care — After 4-6 weeks of appropriate standard treatment (debridement, offloading, dressings, infection management) without significant improvement, Heberprot-P may offer a new approach. • Multiple U.S. treatments have been tried without success — NPWT, HBOT, skin substitutes, and becaplermin have been used without healing. • Amputation is being discussed — If your U.S. physician has mentioned amputation as a possibility, seeking a second opinion through SMC Salud's medical review is worthwhile before proceeding. • The ulcer is Wagner grade 2-4 — Moderate to deep ulcers that are candidates for growth factor therapy. • Adequate blood supply is present — Doppler studies confirm sufficient circulation to the wound area. • The patient can travel — The patient is medically stable enough for travel to Cuba and a 4-8 week stay.

Heberprot-P is NOT appropriate when: • The ulcer is superficial (Wagner grade 1) and likely to heal with standard care alone. • There is active, uncontrolled infection requiring immediate surgical intervention. • There is severe ischemia (poor blood flow) that cannot be corrected with vascular intervention. • There is malignancy in the wound area. • The patient is not medically stable enough for travel.

SMC Salud's medical team reviews each case individually to determine whether Heberprot-P is appropriate before the patient travels. This honest, case-by-case assessment ensures that only suitable candidates undertake the journey to Cuba.